🟢 MRNA is trading 6.9% up today on hantavirus vaccine development and positive flu vaccine progress

MRNA is trading at $58.20 in pre-market, up 6.9% following the announcement of early-stage hantavirus vaccine development and positive progress in its flu vaccine program.

• The hantavirus vaccine is being developed in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University in response to a recent cruise ship outbreak.
• The surge builds on Friday's 11.97% gain, reflecting strong investor confidence in the company's expanding pipeline and its ability to rapidly respond to emerging infectious disease threats.